PT  - JOURNAL ARTICLE
AU  - Richard E. Grewelle
AU  - Giulio A. De Leo
TI  - Estimating the Global Infection Fatality Rate of COVID-19
AID  - 10.1101/2020.05.11.20098780
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.11.20098780
4099  - http://medrxiv.org/content/early/2020/05/18/2020.05.11.20098780.short
4100  - http://medrxiv.org/content/early/2020/05/18/2020.05.11.20098780.full
AB  - COVID-19 has become a global pandemic, resulting in nearly three hundred thousand deaths distributed heterogeneously across countries. Estimating the infection fatality rate (IFR) has been elusive due to the presence of asymptomatic or mildly symptomatic infections and lack of testing capacity. We analyze global data to derive the IFR of COVID-19. Estimates of COVID-19 IFR in each country or locality differ due to variable sampling regimes, demographics, and healthcare resources. We present a novel statistical approach based on sampling effort and the reported case fatality rate of each country. The asymptote of this function gives the global IFR. Applying this asymptotic estimator to cumulative COVID-19 data from 139 countries reveals a global IFR of 1.04% (CI: 0.77%,1.38%). Deviation of countries’ reported CFR from the estimator does not correlate with demography or per capita GDP, suggesting variation is due to differing testing regimes or reporting guidelines by country. Estimates of IFR through seroprevalence studies and point estimates from case studies or sub-sampled populations are limited by sample coverage and cannot inform a global IFR, as mortality is known to vary dramatically by age and treatment availability. Our estimated IFR aligns with many previous estimates and is the first attempt at a global estimate of COVID-19 IFR.Competing Interest StatementThe authors have declared no competing interest.Funding StatementREG is funded by the Stanford Graduate Fellowship and Stanford Biology Department.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data was collected from publicly available repositories. https://www.worldbank.org/ https://www.worldometers.info/coronavirus/ https://github.com/pcm-dpc/COVID-19/tree/master/dati-regioni